Masahiro Rokugo

Also affiliated with Harvard University, Tohoku University, Dana-Farber Cancer Institute, National Cancer Center Hospital East

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy”.

MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy

JCI Insight(2025)10.1172/jci.insight.190924

N/A

0.373DataRank · unranked

11 citations

Tatsuaki Daimon, Hiroshi Hongo, Sheng-Yu Ku, Hiroki Ozawa, Naoki Haratake +14 more

Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer

Oral Oncology(2024)10.1016/j.oraloncology.2024.106795

N/A

0DataRank · unranked

6 citations

Shin Saito, Masahiro Rokugo, Ann Marie Egloff, Ravindra Uppaluri, Michihisa Kono